GlassScriptPhysician profile
Shimin Cao
NPI 1922100213
$13,770.50
in general payments reported to CMS, 2019-2025
35 companies · $2,814 in 2025
The $2,814 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $1,748 · 2021: $1,493 · 2022: $1,980 · 2023: $2,488 · 2024: $2,559 · 2025: $2,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,861.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,173.47 | 2019-2025 | Vemlidy |
| Novo Nordisk INC | $950.22 | 2019-2025 | Rybelsus, Ozempic |
| Teva Pharmaceuticals USA, INC. | $949.96 | 2022-2024 | Uzedy, Austedo Xr, Austedo |
| Amgen INC. | $909.16 | 2019-2025 | Evenity, Prolia, Repatha |
| Neurocrine Biosciences, INC. | $837.82 | 2021-2025 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $743.38 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $601.95 | 2021-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $592.49 | 2020-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $575.72 | 2023-2025 | Airsupra, Farxiga |
| Axsome Therapeutics, INC. | $512.88 | 2023-2025 | Auvelity |
| Abbvie INC. | $413.34 | 2019-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $376.44 | 2022-2025 | Shingrix, Arexvy, Nucala |
| Alkermes, INC. | $374.24 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Lilly USA, LLC | $319.50 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $314.04 | 2020-2024 | Gardasil 9, Gardasil, Capvaxive |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $293.56 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $286.49 | 2019-2024 | Rexulti |
| Amarin Pharma, INC. | $282.91 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $144.40 | 2022 | |
| Scilex Pharmaceuticals INC. | $130.13 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2024 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $116.25 | 2024 | Fanapt |
| Kowa Pharmaceuticals America, INC. | $114.03 | 2024-2025 | Zoryve |
| Intra-Sana Laboratories | $77.74 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Pfizer INC. | $75.42 | 2024 | |
| Phathom Pharmaceuticals, INC. | $70.63 | 2024-2025 | Voquezna |
| Ani Pharmaceuticals, INC. | $67.40 | 2025 | Purified Cortrophin Gel |
| Exact Sciences Corporation | $57.67 | 2023-2025 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $37.21 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.97 | 2024 | Invega Sustenna |
| Lexicon Pharmaceuticals, INC. | $28.74 | 2024 | |
| Edwards Lifesciences Corporation | $27.30 | 2023 | Sapien 3 Ultra Resilia |
| Ardelyx, INC. | $23.44 | 2024 | Ibsrela |
| Oxford Immunotec USA INC | $12.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shimin Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.